Clinical Trials Logo

Recurrent Anaplastic Astrocytoma clinical trials

View clinical trials related to Recurrent Anaplastic Astrocytoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03893487 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Fimepinostat in Treating Brain Tumors in Children and Young Adults

PNOC016
Start date: August 7, 2019
Phase: Early Phase 1
Study type: Interventional

This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02796261 Active, not recruiting - Clinical trials for Anaplastic Astrocytoma

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

STELLAR
Start date: July 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

NCT ID: NCT02192359 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Start date: March 7, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.